PDL BioPharma Plans To Divest Assets, Emerge As Pure Play Biotech
This article was originally published in The Pink Sheet Daily
Executive Summary
Sale of PDL’s lucrative royalty stream or even the company itself is not off the table as reorganization unfolds.
You may also be interested in...
PDL Ditches Cardene, Other Heart Failure Meds As Part Of Restructuring Plan
In a surprise move, former ESP Pharma executive snaps assets back up from PDL at what some consider a bargain-basement price.
PDL Ditches Cardene, Other Heart Failure Meds As Part Of Restructuring Plan
In a surprise move, former ESP Pharma executive snaps assets back up from PDL at what some consider a bargain-basement price.
PDL Now Says It Will Consider Sale Of Entire Company
CEO McDade formally steps down, while former board chairman Gage becomes interim CEO.